Loading clinical trials...

RECRUITING

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

NCT03667417•Institut Paoli-Calmettes

View on ClinicalTrials.gov

Summary

Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers

Detailed Description

Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.
•1. Woman with or without breast cancer or ovarian cancer at baseline.
•2. Man with or without breast cancer at baseline.
•2. Signed consent to participation
•3. Affiliation to a social security regimen, or beneficiary of such a regimen.

Exclusion Criteria

•1. A person of legal age subject to a legal protection measure, or unable to express consent.
•2. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons

Locations (1)

Institut Paoli-Calmettes

Marseille, France

Key Dates

Start Date

October 15, 1999

Primary Completion Date

October 15, 2028

Completion Date

October 15, 2028

Last Updated

July 1, 2020

Enrollment

5,000

ESTIMATED participants

Conditions

Breast CancersOvarian Cancers

Interventions

Questionnaires

OTHER

Contacts

Dominique GENRE, MD

CONTACT

33 491 22 37 78 DRCI.UP@ipc.unicancer.fr

Margot BERLINE, MSc, MBA

CONTACT

33 491 22 33 14 DRCI.UP@ipc.unicancer.fr

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

NCT06774027

HER2-negative Breast CancerHER2 Negative Breast Carcinoma+4 more

View study

RECRUITINGPHASE1/PHASE2

A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

NCT06811870

Breast Cancers

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

Inclusion Criteria

Exclusion Criteria

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

Breast Cancer PET/CT Imaging With 68Ga-pAKTi

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Clinicopathological Parameters of HER2 Low Breast Cancers